Research in the field has to deal with intrinsic complexity and heterogeneity, taking into account the different molecular subtypes of gliomas (e.g., IDH wild type vs. mutation), grading (low- and high grade), classification in use, and typologies of therapies. The gene discussed is IDH1; the disease is glioma.